Mobile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaired G...

Mise à jour : Il y a 5 ans
Référence : EUCTR2005-002778-30

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaired Glucose Tolerance (IGT)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the efficacy of vildagliptin in subjects with IGT by testing the hypothesis that vildagliptin 50 mg qd reduces the area under the 0-2 hour prandial plasma glucose curve (AUC0-2hr) more than placebo following a standard meal challenge after 12 weeks of treatment.

Critère d'inclusion

  • Type II Diabetes

Liens